Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China

Jinjun Ran, Ying Song, Zian Zhuang, Lefei Han, Shi Zhao, Peihua Cao, Yan Geng, Lin Xu, Jing Qin, Daihai He, Fengfu Wu, Lin YangHypertension 2020 · DOI

Introduction

During the initial stages of the COVID-19 pandemic, hypertension was frequently identified as a major comorbidity among hospitalized patients, significantly elevating the risk of severe disease and mortality. However, clinical management faced two critical uncertainties: first, whether the quality of blood pressure (BP) control during hospitalization influenced outcomes beyond the mere presence of the diagnosis; and second, whether the use of Angiotensin-Converting Enzyme inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) might exacerbate the infection by increasing ACE2 expression. This retrospective study investigates these questions by analyzing in-hospital BP metrics and medication use in a cohort of hypertensive patients in Wuhan, China.

Methods

The researchers conducted a retrospective cohort study using anonymized electronic medical records from Huoshenshan Hospital, a specialized field hospital established during the peak of the outbreak in Wuhan (February to March 2020).

Cohort Selection

From an initial pool of 3,023 COVID-19 patients, the study focused on 803 individuals who met the criteria for a confirmed hypertension diagnosis and had sufficient blood pressure records for analysis. Patients without coexisting hypertension or those with suspected rather than confirmed COVID-19 were excluded to ensure data integrity.

Flowchart of the patient selection process, detailing the exclusion criteria that led to the final cohort of 803 hypertensive patients.

Statistical Approach

Beyond standard admission BP, the study calculated average in-hospital BP, Pulse Pressure (PP), and Blood Pressure Variability (BPV), defined as the standard deviation (SD) of daily mean readings. Cox proportional hazards models were utilized to estimate Hazard Ratios (HR) for four primary adverse outcomes: mortality, ICU admission, respiratory failure, and heart failure. The models were adjusted for potential confounders, including age, sex, baseline disease severity, and other comorbidities.

Key Insights and Results

The Significance of Blood Pressure Variability

One of the study's most significant findings is that the stability of blood pressure is as predictive of outcomes as the absolute BP level. High BP variability—the degree to which a patient's pressure fluctuates day-to-day—was independently associated with increased risks of mortality and ICU admission. This suggests that unstable BP may serve as a clinical marker for autonomic dysfunction or extreme systemic stress during the course of the infection.

Hazard ratios for mortality, ICU admission, and heart failure plotted against the standard deviation (SD) of systolic blood pressure, illustrating the increased risk associated with high BP variability.

Blood Pressure Levels and Cardiac Complications

The analysis revealed a strong correlation between poor systolic BP control and the development of heart failure. Specifically, every 10 mmHg increase in average systolic BP (SBP) was associated with an 89% increase in heart failure risk (HR 1.89). Furthermore, Pulse Pressure (the difference between systolic and diastolic readings) proved to be a more potent predictor of heart failure than average SBP alone, likely reflecting underlying arterial stiffness and diminished cardiac reserve in these patients.

Safety and Potential Benefits of ARBs

The study provided crucial evidence regarding the safety of ARB medications. Contrary to early pandemic fears, ARB use did not increase the risk of adverse outcomes. In fact, patients treated with ARBs demonstrated a significantly lower risk of ICU admission (HR 0.21, 95% CI: 0.06–0.73) compared to non-users. This finding supports the clinical recommendation to continue ARB therapy in hypertensive patients infected with SARS-CoV-2.

Discussion and Limitations

The results underscore the importance of rigorous in-hospital BP management. Monitoring both the average levels and the day-to-day variability of blood pressure can provide valuable prognostic information. The observed safety profile of ARBs offers reassurance to clinicians and patients alike.

However, the study's retrospective design means it can only establish associations, not definitive causation. Additionally, because many patients were admitted 2–3 weeks after the onset of symptoms, the impact of BP control during the very early stages of infection remains unassessed. The lack of pre-hospitalization baseline data and the single-center nature of the study also suggest that further prospective research across diverse populations is necessary to confirm these findings.

Conclusion

Effective management of both blood pressure levels and variability is essential for improving outcomes in hypertensive COVID-19 patients. The continuation of ARB therapy appears safe and potentially beneficial, highlighting the need for personalized cardiovascular care within the context of viral respiratory infections.

Summary updated

BibTeX
@inproceedings{ran2020blood,
  author = {Jinjun Ran and Ying Song and Zian Zhuang and Lefei Han and Shi Zhao and Peihua Cao and Yan Geng and Lin Xu and Jing Qin and Daihai He and Fengfu Wu and Lin Yang},
  title = {{Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China}},
  booktitle = {Hypertension},
  year = {2020},
  doi = {10.1038/s41440-020-00541-w},
}
Figure